Compare AbbVie Inc (ABBV) vs United States Oil ETF (USO) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

USO trades at $117.98, down 0.75% amid bearish technical signals with 13 sell indicators versus 4 buy signals. The stock faces pressure from Middle East tensions affecting oil markets, though RSI levels suggest potential oversold conditions. Recent news highlights ongoing Strait of Hormuz deadlock and declining Strategic Petroleum Reserve levels, creating volatility in energy sector valuations.

The outlook remains cautious with technical weakness and geopolitical uncertainty weighing on sentiment. Investment opportunity exists for contrarian buyers given oversold RSI levels, but risks include prolonged Middle East tensions and oil price volatility. Fundamental analysis is limited without current financial ratios available.